Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

High-throughput approaches to uncover synergistic drug combinations in leukemia

SLAS DISCOVERY(2023)10.1016/j.slasd.2023.04.004Source: DataRank Database

High-throughput approaches to uncover synergistic drug combinations in leukemia is a dataset published in SLAS DISCOVERY (2023). On theSindex it has a DataRank of 0.446, placing it in the top 42.2% of the data-sharing corpus. It has been cited 9 times, with 7 citing works in its 1-hop citation network.

Top 42%percentile

0.446DataRank

Ranks in the top 42% for downstream scientific impact

Data paper Open Access9 citations · 7 citing works in its network

Download PDF

Cite:

Linked data & code

gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 0.83)OA: goldTopics (32)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (1/3)

Dataset classification

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 77%Citation Network 23%

Base Score Contribution

0.345

From this paper's citation signal

Citation Network Contribution

0.101

From 5 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 7 citers.

Synergy and antagonism between azacitidine and FLT3 inhibitors
Computers in Biology and Medicine20236 citations47 referencesContributes 0.041
Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis
Cancer Letters20255 citations59 referencesContributes 0.030
Ex vivo discovery of synergistic drug combinations for hematologic malignancies
SLAS DISCOVERY20233 citations61 referencesContributes 0.023
Inhibitory function of CDK12i combined with WEE1i on castration-resistant prostate cancer cells in vitro and in vivo
ONCOLOGIE20231 citations48 referencesContributes 0.014
Phosphodiesterase 3A modulators sensitize tumor cells to Bcl-xL and Bcl-2/Bcl-xL inhibitors
bioRxiv (Cold Spring Harbor Laboratory)20251 citations70 referencesContributes 0.010

Authors (18)

Meng Wang ORCID,Michele Ceribelli ORCID,Aleksandra M. Michalowska,Stefan Golas ORCID,Erin Beck ORCID

Live enrichment

PubMed:37121274 PMC:PMC10449086 OpenAlex:https://openalex.org/W4367396241

National Cancer Institute

Grant: F32 CA247274-01

NIGMS

Grant: R01GM144601

NCI NIH HHS

Grant: F32 CA247274

Andrew McDonough B+ Foundation

CancerFree KIDS

Israel National Road Safety Authority

National Center for Advancing Translational Sciences

National Institutes of Health

Mark Foundation For Cancer Research

St. Baldrick's Foundation

Nationwide Children's Hospital

FWCI

0.83

Citation Percentile

0.7%

Citation Trend

2023

2025

goldLicense: cc-by-nc-nd

journalhttp://slas-discovery.org/article/S2472555223000357/pdf

publisherhttp://slas-discovery.org/article/S2472555223000357/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2472555223000357?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2472555223000357?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.slasd.2023.04.004

Fields of Study

Protein Degradation and InhibitorsGenomics and Chromatin DynamicsEpigenetics and DNA MethylationHumansMyeloid-Lymphoid Leukemia ProteinHistone-Lysine N-MethyltransferaseLeukemia, Myeloid, AcuteDrug CombinationsDrug Evaluation, Preclinical

MeSH Terms

Drug CombinationsDrug Evaluation, PreclinicalHumansHistone-Lysine N-MethyltransferaseLeukemia, Myeloid, AcuteMyeloid-Lymphoid Leukemia Protein

Keywords

DrugContext (archaeology)Computer scienceWorkflowComputational biologyMyeloid leukemiaBiologyPharmacologyCancer researchDatabaseAcute myeloid leukemiaCombination indexsynergyEpigeneticsCombination therapyPrecision MedicineOpen-source Automation

Sustainable Development Goals

SDG 0: Good health and well-being